Eric joined F-Prime in 2021 as a Venture Partner focused on executive leadership and go-to-market functions in technology and cybersecurity companies. Eric has founded and helped lead organizations from startup to $100 million plus revenue, including RiskRecon (acquired by Mastercard), Trusteer (acquired by IBM), Imprivata (IPO), and Centra Software (IPO).
Eric earned his undergraduate degree from Wharton School of University of Pennsylvania and his MBA from MIT Sloan School of Management.
Dr. Namandjé N. Bumpus joined F-Prime in 2025, where she serves as a strategic advisor on regulatory science, regulatory affairs, and policy, bringing deep expertise from her previous roles as FDA Principal Deputy Commissioner and Chief Scientist. Before the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and director of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine, where her research advanced understanding of drug metabolism, mechanisms of drug-induced toxicity, pharmacogenetics, bioanalytical chemistry, infectious disease pharmacology, and single cell biology. She completed her postdoctoral fellowship at The Scripps Research Institute and holds a PhD in pharmacology from the University of Michigan and a bachelor’s degree in biology from Occidental College.
Dr. Bumpus is a past-president of the American Society for Pharmacology and Experimental Therapeutics, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine.
Catherine Stehman-Breen is a Venture Partner at F-Prime based in the Cambridge office, focusing on new company creation. She has more than 30 years of medical and biopharmaceutical experience. Prior to joining F-Prime, Catherine was CEO of Chroma Medicine, a company developing a novel epigenetic editing therapeutics platform where she built the company from inception. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics, a cell therapy company developing engineered tumor infiltrating lymphocyte therapies for patients with solid tumors. As Entrepreneur in Residence at Atlas Venture, she worked closely with start-ups across a range of technologies and previously served as Chief Medical Officer at Sarepta Therapeutics. In addition, Catherine held various leadership roles at Regeneron and Amgen.
Catherine earned her MD from the University of Chicago. She completed her residency and nephrology fellowship training at the University of Washington, where she also received an MS in epidemiology. Catherine served as a faculty member in the division of nephrology and remains an affiliate associate professor in the University of Washington School of Public Health, with more than 90 publications in medical journals.
Michelle is the Director of Compliance and Risk at F-Prime. Michelle has more than 15 years of compliance and legal experience—leading several enterprise-wide compliance programs, including political law. Most recently, Michelle supported Fidelity Digital Assets®, a subsidiary of Fidelity Investments dedicated to digital assets. Prior to joining Fidelity, Michelle practiced law focusing on areas such as commercial bankruptcy, estate planning, business formation, immigration, and family violence protective orders.
Michelle received her law degree from Texas Wesleyan University School of Law (now Texas A&M University School of Law), and holds a BBA in Finance, magna cum laude, and MBA from the University of Texas at Arlington.
Jingwei is a Senior Associate at F-Prime, investing at the intersection of fintech and digital assets, with a focus on the core infrastructure that underpins modern financial and economic systems.
Earlier in his investing career, Jingwei focused exclusively on fintech. That experience shaped his conviction that while application-layer innovation can meaningfully expand access and improve usability, the next wave of progress depends on modernizing the underlying infrastructure. He now focuses on digital assets as one of the core building blocks enabling that transition across payments, private markets, and capital markets.
Before joining F-Prime, Jingwei worked at Boston Consulting Group, where he developed a ground-level understanding of how large organizations evaluate growth, risk, and technology adoption. He began his career at the Bank of England, gaining rare, inside perspective on how the financial system itself is constructed and governed at its core.
Jingwei holds an MSc in Finance from Imperial College London. His exposure to digital assets began in 2017, when he helped launching a blockchain-native digital bank that raised $20 million via a public token sale.
Claire Knowlton joined F-Prime in 2025 as a Marketing Associate. Claire supports marketing initiatives through event planning and internal communications. Previously, she worked at an estate planning law firm, focusing on email and social media marketing.
Claire holds a BA in Marketing from Loyola University Chicago.
Abby Wagner joined F-Prime in September 2024, and currently holds a Senior Accountant role. She previously held an Assurance Senior position at Ernst & Young, LLP serving primarily private clients in the wealth and asset management industry.
Abby earned an MBA and BS in Accounting with a Minor in Finance from Auburn University.
Lucia is an Executive Assistant and the Office Manager of F-Prime’s San Francisco Office. Lucia supports a number of Principals across the firm’s San Francisco and Cambridge offices.
Prior to F-Prime, Lucia was Executive Assistant to the Dean of Harvard’s John A. Paulson School of Engineering and Applied Sciences. Lucia also previously held EA and Development Associate roles at a non-profit in the Boston area, after transitioning from roles in Music.
Lucia received her M.M. in Collaborative Piano from the New England Conservatory of Music, and B.A. in Piano Performance from University of California, Santa Cruz.
Natasha Rodgers is an Associate in F-Prime’s London team, working across the life sciences sub-sectors including therapeutics and medical technology. Prior to joining F-Prime, Natasha was an associate consultant at Bain & Company. She also worked as a junior doctor in Edinburgh and Oxford with a particular focus area in Intensive Care.
Natasha holds an MB BChir from Cambridge University and an A.B. in Molecular and Cellular Biology from Harvard University.
Rosanne Yang is Senior Legal Counsel at Fidelity Investments and supports the F-Prime team on legal aspects of the firm’s operations, including portfolio company investments and exits, fund formation, ongoing fund administration, and day-to-day management company operations.
Rosanne joined Fidelity in 2024 from Goodwin Procter, where she was a Senior Associate in the firm’s Technology and Life Sciences groups. Rosanne has many years of legal experience counseling venture capital and private equity firms, public and private companies, and entrepreneurs on a variety of legal matters. While working at Goodwin Procter, she also served as a Legal Secondee for Bain Capital Life Sciences, offering insights on a broad spectrum of legal and compliance issues. Over the course of her legal career, Rosanne has worked across a broad spectrum of industries, including biotechnology, health care, medical devices, pharmaceuticals, software, information technology and financial services.
Rosanne received her J.D. from Columbia Law School, where she was a James Kent Scholar and an editor of the Columbia Journal of European Law. She received her LL.B from Peking University in International Studies, and her Master’s degree in International Affairs from Sciences Po Paris.
Rosanne is admitted to the Massachusetts and the New York bars.